Expertise in
1
conditions

Ziling Y. Liu

No. 2699, Qianjin Street, 
Changchun, CN 
Expertise in
1
conditions
No. 2699, Qianjin Street, 
Changchun, CN 

Overview

Ziling Liu practices practicing medicine in Changchun, China.

Liu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Paronychia, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Metastases.

They are actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 2699, Qianjin Street, Changchun, 130012, China
Other Locations
71 Xinmin Avenue, Changchun, 130021, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib
Study Phase: Phase 2
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib, Sunitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

72 Total Publications

Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition.
Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition.
Journal: Frontiers in immunology
Published: February 24, 2026

Frequently Asked Questions about Ziling Y. Liu

Is Ziling Y. Liu a top-rated expert for Paronychia?

MediFind is an objective health platform that identifies experts based on real-world data. Ziling Y. Liu is classified as an Advanced expert for Paronychia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ziling Y. Liu participate in research or clinical trials?

Yes. Ziling Y. Liu has published 72 articles and abstracts on conditions like Paronychia. You can view a list of Ziling Y. Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile